Fig. 4: Impact of mTOR pathway mutations on patient DSS.

Survival analysis was performed with patients grouped according to MTOR/TSC1/TSC2 mutation status in: (a) this study and (b) in TCGA-KICH. The P values included in the graph correspond to the log-rank test.